SHIFT Newsroom · GLOBAL
Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss: An Updated Review
Researchers have published an updated systematic review on the efficacy and safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for weight loss in adults without diabetes.
An updated systematic review has been published on the efficacy and safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for weight loss in adults without diabetes. The review provides new insights into the potential use of these agents for weight loss, but more evidence is needed to fully understand their efficacy and safety.
SHIFT’s take
This review may inform future decisions on the use of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for weight loss in the UK, potentially impacting treatment options for adults without diabetes.
Known facts
- Glucagon-like Peptide-1 Receptor Agonists and Co-agonists are being researched for their efficacy and safety in weight loss among adults without diabetes.